FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

FDA decision on Anitocabtagene Autoleucel (anito-cel) in 2026 If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own